@misc{misc, title = {{345 Treatment with amlitelimab鈥攁 novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody鈥攔educes IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis}}, url = {{}}, year = {{2023}}, month = {{1}}, author = {{Weidinger S and Cork M and Reich A and Bieber T and Gilbert S and Brennan N and Wilson R and Lucchesi D and Rynkiewicz N and Stebegg M and Porter-Brown B}}, note = {{Accessed on 2025/05/20}}}